Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
55.15
+1.38 (+2.57%)
Official Closing Price
Updated: 4:15 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
34
35
Next >
My 5 Top Growth Stocks to Buy Hand Over Fist for 2024
↗
January 14, 2024
2024 could be a year of growth.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
↗
January 13, 2024
These companies could stand out thanks to game-changing technology.
Via
The Motley Fool
2 Red Flags for Bluebird Bio Stock
↗
January 10, 2024
The biotech's struggles may continue.
Via
The Motley Fool
3 Cathie Wood Stocks to Start Off Your New Year Right
↗
January 10, 2024
The following stocks could deliver big gains over time.
Via
The Motley Fool
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
↗
January 01, 2024
Via
Benzinga
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
↗
December 22, 2023
There are plenty of reasons to be optimistic about CRISPR's future.
Via
The Motley Fool
The Ultimate Growth Stock to Buy With $1,000 Right Now
↗
January 08, 2024
The stock, trading for about $60, has plenty of room to run.
Via
The Motley Fool
5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024
↗
January 06, 2024
You'll find exciting innovators across industries.
Via
The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
↗
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
2 Biotech Stocks With Huge Catalysts in 2024
↗
January 05, 2024
Important clinical-trial readouts on the way could send these stocks soaring in early 2024.
Via
The Motley Fool
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
↗
January 04, 2024
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent.
Via
InvestorPlace
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
↗
January 04, 2024
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.
Via
The Motley Fool
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
↗
January 03, 2024
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside.
Via
InvestorPlace
Better Risky Investment: Bluebird Bio vs. Shiba Inu
↗
January 03, 2024
Few investors dare to tread where the ice is known to be very thin.
Via
The Motley Fool
3 Biotech Stocks Set for Breakthroughs in 2024
↗
January 02, 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.
Via
InvestorPlace
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
3 No-Brainer Growth Stocks to Buy for Less Than $100
↗
January 01, 2024
These businesses have promising futures and make for great investment options today.
Via
The Motley Fool
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
↗
December 31, 2023
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.
Via
The Motley Fool
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
↗
December 31, 2023
Curing rare inherited illnesses could be a lucrative business model.
Via
The Motley Fool
2023 in Review: Nvidia, Interest Rates, Taylor Swift
↗
December 30, 2023
And a little bit of real estate insight.
Via
The Motley Fool
3 Stocks That Could Be Monster Winners in 2024
↗
December 30, 2023
Don't be surprised if these three stocks take off in the new year.
Via
The Motley Fool
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising
↗
December 30, 2023
With the robotics revolution taking over multiple industries, investors have options.
Via
InvestorPlace
Topics
Artificial Intelligence
CRISPR Therapeutics sets sights on gene-editing cures for disease
December 27, 2023
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for
Via
MarketBeat
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
↗
December 25, 2023
These are ideal stocks to buy sooner rather than later.
Via
The Motley Fool
3 Healthcare Technology Stocks to Improve Lives in 2024
↗
December 25, 2023
Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks.
Via
InvestorPlace
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
↗
December 23, 2023
The stock has been in the news lately.
Via
The Motley Fool
Cathie Wood Predicts Deflation In 2024, More AI And Tech Optimism — And Rate Cuts
↗
December 22, 2023
Cathie Wood believes deflation in 2024, aggressive rate cuts and technological progress will drive expansion.
Via
Benzinga
Topics
Artificial Intelligence
Economy
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
↗
December 22, 2023
Doing a little math and doing a little extra research can make a big difference.
Via
The Motley Fool
I'm Begging You to Buy Stocks Before January -- Here's Why
↗
December 22, 2023
Some studies have shown a pattern of market gains in the month of January.
Via
The Motley Fool
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.